Bevacizumab, a monoclonal antibody against VEGF-A, both alone [52] and in combination liposomal doxorubicin [53] led to modest responses, but the overall response rate was less as compared to other approved KS therapies. This evidence concerns the gene VEGFA and Kaposi's sarcoma.